Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Meridian Community College recognizes scholastic achievements by publishing the President's and Dean’s lists after the ...

Many celebrities are investing in NWSL franchises, including Kevin Durant, Serena Williams, Patrick Mahomes and more.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

Eli Lilly has shared phase 1 data on amylin analog eloralintide, impressing analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.